The USFDA has recently approved capmatinib, a kinase inhibitor for the treatment of adults with metastatic non-small cell lung cancer (NSCLC). The approval was based on a clinical trial in which capmatinib was targeted to study the antitumoral activity in adult patients.
Patients who had NSCLC along with MET exon 14 skipping, epidermal growth factor receptor (EGFR) wild-type, anaplastic lymphoma kinase (ALK) negative status, and at least one measurable lesion were involved in the trial. Evidence-based study: Title To interpret the anti-cancer activity of capmatinib Phase Phase 2 Study type Interventional Study design Open-label, multicentered, non-randomized Study drug Capmatinib Indications Non-small cell lung cancer Arms 600 mg (tablet) or 400mg (Capsule) twice daily Key Inclusion criteria Stage IIIB or Stage IV of NSCLC Mutations (specific) Key Primary outcome Overall response rate…
